Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE reports developments in drug discovery and development services, integrated R&D programs and strategic partnerships with pharmaceutical, biotechnology, academic and health-focused organizations. Its updates commonly cover small-molecule, biologics and cell-therapy work; AI/ML-enabled platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling; and therapeutic programs in oncology, cardiovascular and metabolic disease, neurology, immunology and infectious disease.
Recurring news also includes Just - Evotec Biologics manufacturing and biologics-development activity, grant-funded global-health work, preclinical candidate nominations, financial results and business updates. Governance items include Supervisory Board nominations, management appointments and operating-model changes tied to the company’s global R&D and partnership infrastructure.
Evotec (NASDAQ:EVO) will report fourth-quarter and full-year 2025 results and provide a business update via webcast and conference call on April 8, 2026.
The live webcast starts at 2:00 pm CEST (8:00 am EDT); registration is required to access the audio, presentation slides, and dial-in details. An on-demand replay will be available on the company website.
Evotec (NASDAQ:EVO) named Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer on April 1, 2026.
Dr. Khan brings over 15 years of international leadership and a track record of closing $7 billion+ in deals; he previously served at Iktos, Proteros and Schrödinger. Evotec has >4,800 employees and >100 proprietary R&D assets.
Evotec (NASDAQ:EVO) subsidiary Just - Evotec Biologics has been selected by BARDA's BioMaP-Consortium to optimize manufacturing for a monoclonal antibody cocktail against Ebola virus (EBOV) and Sudan virus (SUDV).
The multi-year award is valued at up to $10 million if all options are exercised and covers molecular optimization, cell line development and process scale-up to support emergency deployment.
Evotec (NASDAQ:EVO) announced that Bristol Myers Squibb has initiated a Phase 1 clinical study of CELMoD agent BMS-986506 in advanced clear cell renal cell carcinoma, and Evotec will receive a $10 million milestone payment. The trial start advances the Evotec‑BMS protein degradation collaboration and validates Evotec's PanOmics and PanHunter discovery platform.
Evotec (NASDAQ:EVO) announced that its Seattle subsidiary, Just - Evotec Biologics, received a Gates Foundation grant (INV072135) to fund AI-driven molecular optimization of monoclonal antibodies and other biologics.
The grant will support ten J.MD™ projects over three years, using the J.MD™ molecular design suite within the J.DESIGN™ platform to improve titer, pharmacokinetics, immunogenicity, stability and manufacturability to reduce cost of goods and expand global access for low- and middle-income countries.
This continues a collaboration dating to 2014 with prior cGMP campaigns for RSV, malaria, and HIV antibodies.
Evotec (NASDAQ:EVO) announced on January 2, 2026 the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations.
Dr. Fakih will lead a newly integrated Global Communications and Investor Relations function and report directly to CEO Dr. Christian Wojczewski to strengthen alignment, clarity and stakeholder engagement. The move follows the departure of Volker Braun, who led investor relations and ESG for five years. Dr. Fakih brings more than 15 years of life‑sciences experience and prior senior roles at QIAGEN, MorphoSys and CureVac, and holds a PhD in Chemistry.
Evotec (NASDAQ:EVO) closed the sale of Just - Evotec Biologics' Toulouse site to Sandoz, effective 05 December 2025, announced 08 December 2025.
The agreement includes approx. US$350m cash, upfront technology license fees for Evotec's continuous manufacturing platform, and potential additional license fees and success-based development revenues of more than US$300m, replacing existing contractual commitments. Total potential payments may exceed US$650m, plus royalties on up to 10 biosimilars (six tied to originator net sales of US$90bn).
Evotec says the deal is immediately earnings accretive and advances an asset-light strategy to improve revenue mix, margins, and capital efficiency while continuing development and manufacturing services in the U.S. and Europe.
Evotec (NASDAQ:EVO) confirmed that partner Bayer has initiated a Phase 2 clinical study of BAY 3401016, a monoclonal antibody targeting Semaphorin-3A (Sema3A) for the treatment of Alport syndrome.
The randomized, double-blind, placebo-controlled Phase 2a ASSESS study with an extension phase will enroll participants aged 18 to 45. Under the 2016 collaboration, Evotec is eligible for a milestone payment upon first patient dosing, which Bayer expects in early 2026, and for further development and sales milestones plus tiered royalties if the program advances to commercialization.
Evotec (NASDAQ:EVO) announced receipt of a US$5 million milestone payment after the U.S. FDA accepted an Investigational New Drug (IND) application for a collaboration-developed CELMoD™ drug candidate.
The candidate, from Evotec's strategic protein degradation partnership with Bristol Myers Squibb initiated in 2018 and expanded in 2022, is expected to enter Phase 1 in 2026. The announcement highlights Evotec's multi-omics and AI-supported drug discovery role and frames the IND acceptance as a regulatory milestone validating the collaboration's progress toward first-in-class molecular glue degraders.
Evotec (NASDAQ:EVO) reported 9M 2025 results with group revenues €535.1m (down 7.1% YoY) and continued softness in early drug discovery (D&PD: €392.1m, -12.3%). Just - Evotec Biologics (JEB) accelerated, with revenues €143.4m, +11.3% and strong non-Sandoz/non-DoD growth. Adjusted Group EBITDA was a €(16.9)m) loss, with underutilization and fixed costs weighing on margins. After period-end, Evotec signed a >US$650m transaction with Sandoz (cash ~US$350m plus >US$300m in future payments) and expects royalties on up to ten biosimilars. Full-year 2025 guidance confirmed: revenues €760–800m; adj. EBITDA €30–50m; 2028 targets: CAGR 8–12% and adj. EBITDA margin >20%.